Wealthspire Advisors (Maryland)’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio SPPI Stock Details SPPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,774	Closed	-$19K	–	2228
2019 Q1	$19K	Buy	1,774 +1,518	+593%	+$16.3K	﹤0.01%	1305
2018 Q4	$2K	Buy	256 +5	+2%	+$64	﹤0.01%	2163
2018 Q3	$4K	Buy	251 +71	+39%	+$1.54K	﹤0.01%	1956
2018 Q2	$4K	Buy	180 +49	+37%	+$908	﹤0.01%	1933
2018 Q1	$2K	Hold	131	–	–	﹤0.01%	2242
2017 Q4	$2K	Buy	131 +116	+773%	+$2.1K	﹤0.01%	2197
2017 Q3	$0	Buy	+15	New	+$136	﹤0.01%	2520

Other funds holding SPPI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s SPPI Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q2 2019, closing a stake of 1,774 shares — an estimated $19K sold.

Wealthspire Advisors (Maryland) first reported a position in SPPI in Q3 2017 and held it in 7 quarters. The position peaked at $19K in Q1 2019. 165 funds tracked by Wall St. Rank hold SPPI as of Q2 2019.

Wealthspire Advisors (Maryland) reported no remaining Spectrum Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 1,774 Spectrum Pharmaceuticals Inc shares in Q2 2019, an estimated $19K.
Wealthspire Advisors (Maryland) first reported a position in Spectrum Pharmaceuticals Inc in Q3 2017 and held it in 7 quarters.
Wealthspire Advisors (Maryland)'s Spectrum Pharmaceuticals Inc position peaked at $19K in Q1 2019.
165 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.